Evidence map›Paper›PMID 33995529›Full record

ArticleJournal of oncology2021

Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma.

H Barber, A Tofias, B Lander, A Daniels, J Gong, Y Ren, X Ren, Y Liang, P White, K M Kurian

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. A Review of the Application of Spatial Transcriptomics in Neuroscience.Interdisciplinary sciences, computational life sciences · 2024
    Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

H BarberBrain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0002-6619-1001
A TofiasBrain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0002-6457-4340
B LanderBrain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0002-5047-3856
A DanielsBrain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0001-6794-3036
J GongNanoString Technologies, Inc., Seattle, WA, UK.ORCID https://orcid.org/0000-0002-5457-3686
Y RenNanoString Technologies, Inc., Seattle, WA, UK.ORCID https://orcid.org/0000-0001-5173-9022
X RenNanoString Technologies, Inc., Seattle, WA, UK.
Y LiangNanoString Technologies, Inc., Seattle, WA, UK.
P WhiteUniversity of West of England, Bristol, UK.ORCID https://orcid.org/0000-0002-7503-9896
K M KurianBrain Tumour Research Centre, Bristol Medical School, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0003-0303-3716
University of Bristol · GBNanostring Technologies (United States) · USUniversity of the West of England · GB

Funding

Medical Research Council G0701018Medical Research Council G1100578Medical Research Council MR/N004272/1
6 · The paper itself

Abstract

introductionGlioblastoma (GBM) is the most common primary adult brain tumour with a median overall survival (OS) of 12-15 months. Molecular characterization of multiple immunooncology targets in GBM may help target novel immunotherapeutic strategies. We used NanoString GeoMx® Digital Spatial Profiling (DSP) to assess multiple immunooncology protein targets in methylated versus unmethylated IDH-wild-type glioblastoma.

methodsNanoString GeoMx® DSP technology uses multiple primary antibodies conjugated to indexing DNA oligos with a UV photocleavable linker. Tissue regions of interest (ROIs) are selected with bound fluorescent antibodies; oligos are released via a UV-mediated linker and quantitated. We used DSP multiplex analysis of 31 immunooncology proteins and controls (CD4, CD14, CD68, CD8A, B7-H3, PD-L1, CD19, FOXP3, CD44, STAT3 (phospho Y705), CD45, Pan Cytokeratin, MS4A1/CD20, CD45RO, PD1, CD3, beta-2 microglobulin, VISTA, Bcl2, GZMB, PTEN, beta-catenin, CD56, Ki-67, STAT3, AKT, p-Akt, S6, Histone H3, IgG Rabbit control, and Mouse IgG control) from ROIs in a cohort of 10 IDH-wild-type glioblastomas (5 methylated and 5 unmethylated). An nCounter platform allowed quantitative comparisons of antibodies between ROIs in MGMT methylated and unmethylated tumours. Mean protein expression counts between methylated and unmethylated GBM were compared using technical and biological replicates.

resultsThe analysis showed 10/27 immunooncology target proteins were significantly increased in methylated versus unmethylated IDH-wild-type glioblastoma tumour core (false discovery rate (FDR) <0.1 by Benjamini-Hochberg procedure).

conclusionsNanoString GeoMx® DSP was used to analyse multiple immunooncology protein target expression in methylated versus unmethylated IDH-wild-type glioblastoma. In this small study, there was a statistical increase in CD4, CD14, CD68, CD8A, B7-H3, PDL-1, CD19, FOXP3, CD44, and STAT3 protein expression in methylated versus unmethylated GBM tumour core; however, this requires larger cohort validation. Advanced multiplex immunooncological biomarker analysis may be useful in identifying biomarkers for novel immunotherapeutic agents in GBMs.

Identifiers

PMID33995529
PMCPMC8096575
OpenAlexW3127513274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.